Synthesis and Antibacterial Activity of Resveratrol Derivatives

  • Yuanmou Chen
  • Fei Hu
  • Yinghao Gao
  • Na Ji
  • Shaolong Jia
Conference paper
Part of the Lecture Notes in Electrical Engineering book series (LNEE, volume 269)


Resveratrol (3,5,4′-trihydroxy-trans-stilbene), which is a naturally occurring phytoalexin produced by a wide range of plants in response to environmental stress or pathogenic attack, is found in various medical plants. It has attracted increasing attention over the past decade because of its multiple beneficial bioactivity. In this paper, a set of 12 methoxylated trans-stilbene resveratrol analogues were prepared from methoxybenzoic acids. In addition, all compounds have been evaluated for their antibacterial activity against both types of Gram negative and Gram positive bacteria compared to resveratrol. Pharmacological data indicated that several derivatives showed a marked antibacterial activity, especially the most promising compound 2c, which has the low MIC 60~90 μg/mL value compared to the resveratrol. Both minimal inhibitory concentration (MIC) and inhibition zones were determined in order to monitor the efficacy of the synthesized compounds. Certain compounds inhibit bacterial growth with low MIC (μg/mL) value. The substitution pattern of the resveratrol derivatives at electronegative groups such as Cl was most important for the activity. Overall, identification of the potential efficacy of these compounds could serve as the bases for the development of novel antibacterial agents.


Resveratrol derivatives Synthesis Antibacterial activity Structure–activity-relationship 


  1. 1.
    Richard JL (1987) Coronary risk factors the french paradox. Arch Mal Coeur Vaiss 80:17–21Google Scholar
  2. 2.
    Takaoka MJ (1940) Of the phenolic substances of white hellebore. J Faculty Sci 3:1–16Google Scholar
  3. 3.
    Kopp P (1998) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the ‘French paradox’? Eur J Endocrinol 138:619–620CrossRefGoogle Scholar
  4. 4.
    Jang M, Pezzuto JM (1999) Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 25:65–771Google Scholar
  5. 5.
    Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E, Vannini V (2001) Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276:22586−22594Google Scholar
  6. 6.
    Daroch F, Hoeneisen M, Gonzalez CL, Kawaguchi F, Salgado F, Solar H, Garcia A (2001) In vitro antibacterial activity of chilean red wines against helicobacter pylori. Microbios 104:79–85Google Scholar
  7. 7.
    Wang WB, Lai HC, Hsueh PR, Chiou RY, Lin SB, Liaw SJ (2006) Inhibition of swarming and virulence factor expression in proteus mirabilis by resveratrol. J Med Microbiol 55:1313–1321CrossRefGoogle Scholar
  8. 8.
    Zaidi SF, Ahmed K, Yamamoto T, Kondo T, Usmanghani K et al (2009) Effect of resveratrol on helicobacter pylori-induced interleukin-8 secretion, reactive oxygen species generation and morphological changes in human gastric epithelial cells. Biol Pharm Bull 32:1931–1935CrossRefGoogle Scholar
  9. 9.
    Arichi H, Kimura Y, Okuda H, Baba K et al (1982) Effects of stilbene components of the roots of polygonum cuspidatum on lipid metabolism. Chem Pharm Bull (Tokyo) 30:1766–1770CrossRefGoogle Scholar
  10. 10.
    Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM (1996) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235:207–219CrossRefGoogle Scholar
  11. 11.
    Chen CK, Pace-Asciak CR (1996) Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 27:363–366Google Scholar
  12. 12.
    Wood JG et al (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686–689CrossRefGoogle Scholar
  13. 13.
    Howitz KT, Bitterman KJ, Cohen HY, Lamming DW et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196CrossRefGoogle Scholar
  14. 14.
    Wang RH, Sengupta K, Li C, Kim HS, Cao L et al (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14:312–323CrossRefGoogle Scholar
  15. 15.
    Rocha-Gonzalez HI, Ambriz-Tututi M, Granados-Soto V (2008) Resveratrol:A natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther 14:234–247CrossRefGoogle Scholar
  16. 16.
    Vieira de Almeida LM, Pineiro CC, Leite Marina MC, Brolese G, Leal RB, Gottfried C, Goncalves CA (2008) Protective effects of resveratrol on hydrogen peroxide induced toxicity in primary cortical astrocyte cultures. Neurochem Res 33:8–15Google Scholar
  17. 17.
    Ali HA, Kondo K, Tsuda Y (1992) Synthesis and nematocidal activity of hydroxystilbenes. Chem Pharm Bull 40:1130–1136CrossRefGoogle Scholar
  18. 18.
    Thakkar K, Geahlen RL, Gushman M (1993) Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogs of piceatannol. J Med Chem 36:2950–2955CrossRefGoogle Scholar
  19. 19.
    Murias M, Handler N, Erker T et al (2004) Resveratrol analogues as selectivecyclooxygenase-2 inhibitors: synthesis and structure–activityrelationship. Bioorg Med Chem 12:5571–5578CrossRefGoogle Scholar
  20. 20.
    Cristau HJ, Darviche F, Torreilles E (1998) Mechanistic investigations of the formation of TTF derivatives via the phosphonate way. Tetrahedron Lett 39:2103–2106CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Yuanmou Chen
    • 1
  • Fei Hu
    • 1
  • Yinghao Gao
    • 1
  • Na Ji
    • 1
  • Shaolong Jia
    • 1
  1. 1.Key Laboratory of Industrial Microbiology of Ministry of Education College of BiotechnologyTianjin University of Science and TechnologyTianjinChina

Personalised recommendations